A Study of Gastric Delay in Migraine Patients (3207-003)

A Randomized, Double-Blind, Placebo Controlled, 2-Period, Fixed-Sequence Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Orally Administered MK3207 in Patients During and Between Their Acute Migraine Attacks

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00548353

Enrollment

Registered

2007-10-23

Start date

2007-08-31

Completion date

2010-02-28

Last updated

2014-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Disorders

Brief summary

A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.

Interventions

DRUGMK3207

M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).

DRUGComparator: Placebo (unspecified)

M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Non-smoking male or female between 18 to 45 years of age * Patient typically has between 2 and 10 migraine attacks per month, rated as moderate or severe

Exclusion criteria

* Patient has any other medical conditions other than migraine

Design outcomes

Primary

Measure	Time frame
Safety in migraine patients	12 Weeks

Secondary

Measure	Time frame
PK in migraine patients	12 Weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026